Suven Life Sciences shares gained over 4 per cent on BSE on Wednesday after the company informed stock exchanges about the grant of of two product patents from Canada and one product patent from China corresponding to the New Chemical Entities (NCEs) for the treatment of disorders associated with Neurodegenerative diseases and these Patents are valid through 2029 and 2030. The scrip closed 4.27 per cent up at Rs 241.80.
The granted claims of the patents include the class of selective alpha-4-beta-2 compounds discovered by Suven and are being developed as therapeutic agents for major depressive disorder (MDD).
With these new patents, Suven has a total of 20 granted patents from Canada and 18 granted patents from China. These granted patents are exclusive intellectual property of Suven and are achieved through the internal discovery research efforts. Products out of these inventions may be out-licensed at various phases of clinical development like at Phase-I or Phase-II.
The promoters holding in the company stood at 59.44 per cent while institutions and non-institutions held 7.49 per cent and 33.06 per cent, respectively.
Suven Life Science is a biopharmaceutical company focused on discovering, developing and commercializing novel pharmaceutical products, which are first in class or best in class CNS therapies through the use of GPCR targets.